These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38553963)

  • 1. Effects of HIF-PHD inhibitors in kidney development.
    Haraguchi S; Tsuji K; Nakanoh H; Fukushima K; Kitamura S; Wada J
    Nephrol Dial Transplant; 2024 Jul; 39(8):1368-1370. PubMed ID: 38553963
    [No Abstract]   [Full Text] [Related]  

  • 2. Structure-Activity Relationship and Crystallographic Studies on 4-Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors.
    Holt-Martyn JP; Chowdhury R; Tumber A; Yeh TL; Abboud MI; Lippl K; Lohans CT; Langley GW; Figg W; McDonough MA; Pugh CW; Ratcliffe PJ; Schofield CJ
    ChemMedChem; 2020 Feb; 15(3):270-273. PubMed ID: 31751494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ExActa HIF prolyl hydroxylase inhibitors-The new lifestyle drug?
    Sciesielski LK; Kirschner KM
    Acta Physiol (Oxf); 2019 Nov; 227(3):e13370. PubMed ID: 31465609
    [No Abstract]   [Full Text] [Related]  

  • 4. HIF-PHD inhibitor regulates the function of group2 innate lymphoid cells and polarization of M2 macrophages.
    Nagashima R; Ishikawa H; Kuno Y; Kohda C; Iyoda M
    Sci Rep; 2023 Feb; 13(1):1867. PubMed ID: 36725898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
    Wu Y; Jiang Z; You Q; Zhang X
    Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
    Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
    Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia.
    Fukuda T; Kuribayashi T; Takano R; Sasaki K; Tsuji T; Niitsu Y; Ishii K; Hashimoto M; Baba D; Ito S; Tanaka N
    Bioorg Med Chem Lett; 2024 Aug; 108():129799. PubMed ID: 38754564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbon Monoxide is an Inhibitor of HIF Prolyl Hydroxylase Domain 2.
    Mbenza NM; Nasarudin N; Vadakkedath PG; Patel K; Ismail AZ; Hanif M; Wright LJ; Sarojini V; Hartinger CG; Leung IKH
    Chembiochem; 2021 Aug; 22(15):2521-2525. PubMed ID: 34137488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
    Nakai T; Saigusa D; Kato K; Fukuuchi T; Koshiba S; Yamamoto M; Suzuki N
    Life Sci; 2024 Jun; 346():122641. PubMed ID: 38614299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of DS-1093a: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia.
    Tanaka N; Fukuda T; Takano R; Sasaki K; Tsuji T; Goto R; Kuribayashi T; Yamaguchi K; Niitsu Y; Ishii K; Hashimoto M; Takahashi S; Obayashi H
    Bioorg Med Chem Lett; 2024 Oct; 111():129891. PubMed ID: 39019240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia.
    Hamada M; Takayama T; Shibata T; Hiratate A; Takahashi M; Yashiro M; Takayama N; Okumura-Kitajima L; Koretsune H; Kajiyama H; Naruse T; Kato S; Takano H; Kakinuma H
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1725-1730. PubMed ID: 29681433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photoactivatable Prolyl Hydroxylase 2 Inhibitors for Stabilizing the Hypoxia-Inducible Factor with Light.
    Li Z; Su K; Jiang Z; Yu Y; You Q; Zhang X
    J Med Chem; 2019 Aug; 62(16):7583-7588. PubMed ID: 31244107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats.
    Signore PE; Guo G; Wei Z; Zhang W; Lin A; Del Balzo U
    PLoS One; 2021; 16(8):e0255022. PubMed ID: 34339435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia.
    Lawson H; Holt-Martyn JP; Dembitz V; Kabayama Y; Wang LM; Bellani A; Atwal S; Saffoon N; Durko J; van de Lagemaat LN; De Pace AL; Tumber A; Corner T; Salah E; Arndt C; Brewitz L; Bowen M; Dubusse L; George D; Allen L; Guitart AV; Fung TK; So CWE; Schwaller J; Gallipoli P; O'Carroll D; Schofield CJ; Kranc KR
    Nat Cancer; 2024 Jun; 5(6):916-937. PubMed ID: 38637657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
    Wu Y; Jiang Z; Li Z; Gu J; You Q; Zhang X
    J Med Chem; 2018 Jun; 61(12):5332-5349. PubMed ID: 29856623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
    Kular D; Macdougall IC
    Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF-prolyl 4-hydroxylases for treatment of ischemic diseases.
    Selvaraju V; Parinandi NL; Adluri RS; Goldman JW; Hussain N; Sanchez JA; Maulik N
    Antioxid Redox Signal; 2014 Jun; 20(16):2631-65. PubMed ID: 23992027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous?
    Strowitzki MJ; Cummins EP; Taylor CT
    Cells; 2019 Apr; 8(5):. PubMed ID: 31035491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxygen sensors as therapeutic targets in kidney disease.
    Haase VH
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S29-S34. PubMed ID: 28577740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
    Li J; Xie QH; You L; Xu NX; Hao CM
    Pharmacol Res; 2021 Jan; 163():105256. PubMed ID: 33086081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.